flucytosine has been researched along with Glioma in 46 studies
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.
flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "5FC, 5-fluorocytosineBBB, Basso, Beattie, and BresnahanCD, cytosine deaminaseDP, diastolic blood pressureGCV, ganciclovir; hNSCs, human neural stem cellsISCG, intramedullary spinal cord gliomasMAP, mean arterial blood pressureNSCs, neural stem cellsSP, systolic blood pressureTK, thymidine kinase." | 3.83 | Targeted Treatment of Experimental Spinal Cord Glioma With Dual Gene-Engineered Human Neural Stem Cells. ( Abd-El-Barr, M; Aljuboori, Z; Anderson, JE; Chi, JH; Han, I; Haragopal, H; Kim, SU; Lee, HJ; Ropper, AE; Sidman, RL; Snyder, EY; Teng, YD; Viapiano, MS; Zeng, X, 2016) |
| "Since neural progenitor cells can engraft stably into brain tumors and differentiate along the neuronal and glial line, we tested the hypothesis that transplanted cytosine deaminase (CD)-expressing ST14A cells (an immortalized neural progenitor cell line) can convert locally 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU) and produce a regression of glioma tumors." | 3.72 | Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy. ( Barresi, V; Belluardo, N; Cattaneo, E; Condorelli, DF; Mudò, G; Sipione, S, 2003) |
| "In this study, we investigated the feasibility of a double-suicide gene/prodrug therapy, involving direct introduction of the herpes simplex virus Type 1 thymidine kinase (TK) gene and the Escherichia coli cytosine deaminase (CD) gene, via a recombinant adenoviral vector, and ganciclovir (GCV) and/or 5-fluorocytosine (5-FC) treatment, in a rat C6 glioma model." | 3.70 | Combined antitumor effects of an adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma. ( Chang, JW; Chung, SS; Kim, E; Kim, JH; Lee, H; Lee, Y, 2000) |
| "Glioblastoma and anaplastic astrocytoma are two of the most aggressive and common glioma malignancies in adults." | 2.61 | Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma. ( Adamson, DC; Philbrick, BD, 2019) |
| "High-grade gliomas are extremely difficult to treat because they are invasive and therefore not curable by surgical resection; the toxicity of current chemo- and radiation therapies limits the doses that can be used." | 1.39 | Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. ( Aboody, KS; Annala, AJ; Aramburo, S; Badie, B; Barish, ME; Blanchard, S; Brown, CE; Couture, LA; D'Apuzzo, M; Frank, RT; Garcia, E; Gutova, M; Kim, SU; Metz, MZ; Moats, RA; Najbauer, J; Portnow, J; Synold, TW; Valenzuela, VV, 2013) |
| " Survival benefit is dose dependent for both vector and 5-FC, and as few as 4 cycles of 5-FC dosing after Toca 511 therapy provides significant survival advantage." | 1.38 | Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. ( Amundson, KK; Buckley, T; Burnett, R; Chen, CI; Daublebsky, V; Galvão da Silva, AP; Gruber, HE; Gunzburg, W; Hlavaty, J; Ibañez, CE; Jolly, DJ; Kasahara, N; Lin, AH; Lopez Espinoza, F; Martin, B; Ostertag, D; Perez, OD; Pettersson, PL; Robbins, JM; Valenta, DT, 2012) |
| "Immunohistochemistry of rat brain tumors inoculated with MSC-EGFP showed intratumoral distribution of MSC-EGFP." | 1.38 | Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma. ( Date, I; Hamada, H; Ichikawa, T; Inoue, S; Kambara, H; Kosaka, H; Kurozumi, K; Maruo, T; Nakamura, K, 2012) |
| "Medulloblastomas are highly malignant neuroectodermal cerebellar tumors of children." | 1.34 | Human neural stem cells target and deliver therapeutic gene to experimental leptomeningeal medulloblastoma. ( Bang, JH; Fujii, M; Ito, M; Ito, S; Kim, SU; Natsume, A; Park, IH; Shimato, S; Takeuchi, H; Wakabayashi, T; Yoshida, J, 2007) |
| "The infection of RG2 brain tumors with RCR-CD and their subsequent treatment with 5-FC significantly prolonged survival compared with that in animals with RG2 transduced tumors treated with PBS." | 1.33 | Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. ( Chen, TC; Kasahara, N; Kershaw, AD; Klatzmann, D; Solly, SK; Tai, CK; Wang, W, 2006) |
| "Rats bearing 9 L brain tumors were treated with an intratumoral injection of AdexCACD followed by intraperitoneal administration of 5-FC." | 1.31 | In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. ( Adachi, Y; Furuta, T; Hamada, H; Ichikawa, T; Matsumoto, K; Ohmoto, T; Ono, Y; Tamiya, T; Yoshida, Y, 2000) |
| " New interim measures of therapeutic response would be particularly useful in the development of cancer chemosensitization gene therapy by facilitating optimization of gene transfer protocols and prodrug dosing schedules." | 1.31 | Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. ( Chenevert, TL; Hamstra, DA; Jonas, SJ; Rehemtulla, A; Rice, DJ; Ross, BD; Stegman, LD; Stout, KL, 2000) |
| " In vitro studies showed that 5-FC combined with CDase induced significant growth-inhibitory effects on the cultured glioma cells." | 1.27 | Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules. ( Ito, T; Katsuragi, T; Kawamoto, K; Kawamura, Y; Matsumura, H; Nishiyama, T; Ohyama, A; Sakai, T; Yamamoto, N, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.35) | 18.7374 |
| 1990's | 4 (8.70) | 18.2507 |
| 2000's | 17 (36.96) | 29.6817 |
| 2010's | 20 (43.48) | 24.3611 |
| 2020's | 3 (6.52) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SH | 1 |
| Sun, JM | 1 |
| Chen, BM | 1 |
| Lin, SC | 1 |
| Chang, HF | 1 |
| Collins, S | 1 |
| Chang, D | 1 |
| Wu, SF | 1 |
| Lu, YC | 1 |
| Wang, W | 2 |
| Chen, TC | 3 |
| Kasahara, N | 9 |
| Wang, HE | 1 |
| Tai, CK | 3 |
| Accomando, WP | 1 |
| Rao, AR | 2 |
| Hogan, DJ | 4 |
| Newman, AM | 1 |
| Nakao, A | 1 |
| Alizadeh, AA | 1 |
| Diehn, M | 1 |
| Diago, OR | 4 |
| Gammon, D | 4 |
| Haghighi, A | 2 |
| Gruber, HE | 8 |
| Jolly, DJ | 8 |
| Ostertag, D | 7 |
| Cloughesy, TF | 3 |
| Petrecca, K | 1 |
| Walbert, T | 3 |
| Butowski, N | 1 |
| Salacz, M | 1 |
| Perry, J | 1 |
| Damek, D | 1 |
| Bota, D | 1 |
| Bettegowda, C | 1 |
| Zhu, JJ | 2 |
| Iwamoto, F | 1 |
| Placantonakis, D | 1 |
| Kim, L | 1 |
| Elder, B | 1 |
| Kaptain, G | 1 |
| Cachia, D | 1 |
| Moshel, Y | 1 |
| Brem, S | 1 |
| Piccioni, D | 3 |
| Landolfi, J | 3 |
| Chen, CC | 3 |
| Gruber, H | 1 |
| Hogan, D | 1 |
| Accomando, W | 2 |
| Montellano, TT | 1 |
| Kheoh, T | 2 |
| Kabbinavar, F | 1 |
| Vogelbaum, MA | 3 |
| Mitchell, LA | 1 |
| Lopez Espinoza, F | 2 |
| Mendoza, D | 1 |
| Kato, Y | 1 |
| Inagaki, A | 1 |
| Hiraoka, K | 1 |
| Robbins, JM | 5 |
| Elder, JB | 2 |
| Bloomfield, S | 2 |
| Carter, B | 2 |
| Kalkanis, SN | 2 |
| Kesari, S | 2 |
| Lai, A | 2 |
| Lee, IY | 2 |
| Liau, LM | 2 |
| Mikkelsen, T | 2 |
| Nghiemphu, P | 1 |
| Das, A | 3 |
| Lu, G | 1 |
| Carvalho, LA | 1 |
| Teng, J | 1 |
| Fleming, RL | 1 |
| Tabet, EI | 1 |
| Zinter, M | 1 |
| de Melo Reis, RA | 1 |
| Tannous, BA | 1 |
| Sun, CH | 2 |
| Berg, K | 2 |
| Hirschberg, H | 2 |
| Philbrick, BD | 1 |
| Adamson, DC | 1 |
| Aboody, KS | 1 |
| Najbauer, J | 1 |
| Metz, MZ | 1 |
| D'Apuzzo, M | 1 |
| Gutova, M | 1 |
| Annala, AJ | 1 |
| Synold, TW | 1 |
| Couture, LA | 1 |
| Blanchard, S | 1 |
| Moats, RA | 1 |
| Garcia, E | 1 |
| Aramburo, S | 1 |
| Valenzuela, VV | 1 |
| Frank, RT | 1 |
| Barish, ME | 1 |
| Brown, CE | 1 |
| Kim, SU | 4 |
| Badie, B | 1 |
| Portnow, J | 1 |
| Yin, D | 1 |
| Zhai, Y | 1 |
| Ibanez, CE | 3 |
| Kells, AP | 1 |
| Forsayeth, J | 1 |
| Bankiewicz, KS | 1 |
| Parry, PV | 1 |
| Engh, JA | 1 |
| Wang, F | 1 |
| Zamora, G | 1 |
| Trinidad, A | 1 |
| Chun, C | 1 |
| Kwon, YJ | 1 |
| Madsen, SJ | 1 |
| Huang, TT | 1 |
| Parab, S | 1 |
| Burnett, R | 2 |
| Diago, O | 1 |
| Hofman, FM | 1 |
| Espinoza, FL | 1 |
| Martin, B | 2 |
| Pertschuk, D | 1 |
| Ropper, AE | 1 |
| Zeng, X | 1 |
| Haragopal, H | 1 |
| Anderson, JE | 1 |
| Aljuboori, Z | 1 |
| Han, I | 1 |
| Abd-El-Barr, M | 1 |
| Lee, HJ | 1 |
| Sidman, RL | 1 |
| Snyder, EY | 1 |
| Viapiano, MS | 1 |
| Chi, JH | 1 |
| Teng, YD | 1 |
| Nghiemphu, PL | 1 |
| Chu, A | 1 |
| Hanna, M | 1 |
| McCarthy, D | 1 |
| Mitchell, L | 1 |
| Rodriguez-Aguirre, M | 1 |
| Chung, T | 1 |
| Na, J | 1 |
| Kim, YI | 2 |
| Chang, DY | 1 |
| Kim, H | 1 |
| Moon, HE | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Chung, JK | 1 |
| Kim, SS | 1 |
| Suh-Kim, H | 1 |
| Paek, SH | 1 |
| Youn, H | 1 |
| Strebe, JK | 1 |
| Lubin, JA | 1 |
| Kuo, JS | 1 |
| Lv, SQ | 2 |
| Zhang, KB | 1 |
| Zhang, EE | 1 |
| Gao, FY | 1 |
| Yin, CL | 1 |
| Huang, CJ | 1 |
| He, JQ | 2 |
| Yang, H | 3 |
| Shi, DZ | 1 |
| Hu, WX | 1 |
| Li, LX | 1 |
| Chen, G | 1 |
| Wei, D | 1 |
| Gu, PY | 1 |
| Ito, S | 2 |
| Natsume, A | 2 |
| Shimato, S | 2 |
| Ohno, M | 1 |
| Kato, T | 1 |
| Chansakul, P | 1 |
| Wakabayashi, T | 2 |
| Johnson, AJ | 1 |
| Ardiani, A | 1 |
| Sanchez-Bonilla, M | 1 |
| Black, ME | 2 |
| Amundson, KK | 1 |
| Buckley, T | 1 |
| Galvão da Silva, AP | 1 |
| Lin, AH | 1 |
| Valenta, DT | 1 |
| Perez, OD | 1 |
| Chen, CI | 1 |
| Pettersson, PL | 1 |
| Daublebsky, V | 1 |
| Hlavaty, J | 1 |
| Gunzburg, W | 1 |
| Fei, S | 1 |
| Qi, X | 1 |
| Kedong, S | 1 |
| Guangchun, J | 1 |
| Jian, L | 1 |
| Wei, Q | 1 |
| Kosaka, H | 1 |
| Ichikawa, T | 3 |
| Kurozumi, K | 2 |
| Kambara, H | 2 |
| Inoue, S | 1 |
| Maruo, T | 1 |
| Nakamura, K | 1 |
| Hamada, H | 3 |
| Date, I | 1 |
| Barresi, V | 1 |
| Belluardo, N | 1 |
| Sipione, S | 1 |
| Mudò, G | 1 |
| Cattaneo, E | 1 |
| Condorelli, DF | 1 |
| Wang, B | 1 |
| Yoshimura, I | 1 |
| Liu, YS | 2 |
| Tamiya, T | 2 |
| Ono, Y | 2 |
| Otsuka, S | 1 |
| Adachi, Y | 2 |
| Ohmoto, T | 2 |
| Fischer, U | 1 |
| Steffens, S | 1 |
| Frank, S | 1 |
| Rainov, NG | 1 |
| Schulze-Osthoff, K | 1 |
| Kramm, CM | 1 |
| Conrad, C | 1 |
| Miller, CR | 1 |
| Ji, Y | 1 |
| Gomez-Manzano, C | 1 |
| Bharara, S | 1 |
| McMurray, JS | 1 |
| Lang, FF | 1 |
| Wong, F | 1 |
| Sawaya, R | 1 |
| Yung, WK | 1 |
| Fueyo, J | 1 |
| Lü, SQ | 1 |
| Wang, WJ | 1 |
| Kershaw, AD | 1 |
| Solly, SK | 1 |
| Klatzmann, D | 1 |
| Kaliberov, SA | 1 |
| Market, JM | 1 |
| Gillespie, GY | 1 |
| Krendelchtchikova, V | 1 |
| Della Manna, D | 1 |
| Sellers, JC | 1 |
| Kaliberova, LN | 1 |
| Buchsbaum, DJ | 1 |
| Takeuchi, H | 1 |
| Fujii, M | 1 |
| Ito, M | 1 |
| Park, IH | 1 |
| Bang, JH | 1 |
| Yoshida, J | 1 |
| Choi, JD | 1 |
| Powers, CJ | 1 |
| Vredenburgh, JJ | 1 |
| Friedman, AH | 1 |
| Sampson, JH | 1 |
| Nishiyama, T | 2 |
| Kawamura, Y | 2 |
| Kawamoto, K | 2 |
| Matsumura, H | 2 |
| Yamamoto, N | 2 |
| Ito, T | 2 |
| Ohyama, A | 2 |
| Katsuragi, T | 2 |
| Sakai, T | 2 |
| Ge, K | 2 |
| Xu, L | 1 |
| Zheng, Z | 1 |
| Xu, D | 1 |
| Sun, L | 1 |
| Liu, X | 1 |
| Wang, ZH | 2 |
| Samuels, S | 1 |
| Gama Sosa, MA | 1 |
| Kolodny, EH | 2 |
| Xu, LF | 1 |
| Zheng, ZC | 1 |
| Sun, LY | 1 |
| Liu, XY | 1 |
| Zagzag, D | 1 |
| Zeng, B | 1 |
| Matsumoto, K | 1 |
| Furuta, T | 1 |
| Yoshida, Y | 1 |
| Stegman, LD | 1 |
| Rehemtulla, A | 1 |
| Hamstra, DA | 1 |
| Rice, DJ | 1 |
| Jonas, SJ | 1 |
| Stout, KL | 1 |
| Chenevert, TL | 1 |
| Ross, BD | 1 |
| Chang, JW | 1 |
| Lee, H | 1 |
| Kim, E | 1 |
| Lee, Y | 1 |
| Chung, SS | 1 |
| Kim, JH | 1 |
| Moriuchi, S | 1 |
| Wolfe, D | 1 |
| Tamura, M | 1 |
| Yoshimine, T | 1 |
| Miura, F | 1 |
| Cohen, JB | 1 |
| Glorioso, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma[NCT02414165] | Phase 2/Phase 3 | 403 participants (Actual) | Interventional | 2015-11-30 | Terminated (stopped due to Sponsor Decision) | ||
| Phase I Study of Replication-Competent Adenovirus-Mediated Double Suicide Gene Therapy With Stereotactic Radiosurgery in Patients With Recurrent or Progressive High Grade Astrocytomas[NCT05686798] | Phase 1 | 18 participants (Anticipated) | Interventional | 2022-11-29 | Recruiting | ||
| A Phase 1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC[NCT01470794] | Phase 1 | 58 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma[NCT01156584] | Phase 1 | 54 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extende[NCT01985256] | Phase 1 | 17 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for flucytosine and Glioma
| Article | Year |
|---|---|
Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cytosi | 2019 |
5 trials available for flucytosine and Glioma
| Article | Year |
|---|---|
Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Cyt | 2020 |
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neop | 2020 |
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
Topics: Antimetabolites; Brain Neoplasms; Combined Modality Therapy; Cytosine Deaminase; Drug Synergism; Flu | 2018 |
Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients.
Topics: Aged; Animals; Autopsy; Cell Line, Tumor; Cytosine Deaminase; Disease Models, Animal; Female; Flucyt | 2018 |
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.
Topics: Confidence Intervals; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Vectors; Glioma; Prodru | 2016 |
40 other studies available for flucytosine and Glioma
| Article | Year |
|---|---|
Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model.
Topics: Animals; Aziridines; Brain Neoplasms; Cell Line, Tumor; Cytosine Deaminase; Escherichia coli Protein | 2020 |
Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cytosine Deaminase; Disease Model | 2017 |
Olfactory Ensheathing Cells: A Trojan Horse for Glioma Gene Therapy.
Topics: Administration, Intranasal; Animals; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Genetic | 2019 |
Photochemical Internalization Enhanced Nonviral Suicide Gene Therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Fluorou | 2019 |
Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies.
Topics: Animals; Cell Line; Cytosine Deaminase; Female; Flow Cytometry; Flucytosine; Fluorouracil; Glioma; H | 2013 |
Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor model.
Topics: Animals; Brain Neoplasms; Convection; Cytosine Deaminase; Drug Delivery Systems; Flucytosine; Geneti | 2013 |
Neural stem cell-mediated enzyme/prodrug therapy for glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cytosine Deaminase; Flucytosine; Glioma; Humans; Mi | 2013 |
Increased sensitivity of glioma cells to 5-fluorocytosine following photo-chemical internalization enhanced nonviral transfection of the cytosine deaminase suicide gene.
Topics: Antifungal Agents; Cell Line, Tumor; Cytosine Deaminase; Dose-Response Relationship, Drug; Flucytosi | 2014 |
Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.
Topics: Animals; Antibodies, Neutralizing; Antimetabolites; Brain Neoplasms; Clinical Trials as Topic; Cytos | 2015 |
Targeted Treatment of Experimental Spinal Cord Glioma With Dual Gene-Engineered Human Neural Stem Cells.
Topics: Animals; Cytosine Deaminase; Flucytosine; Fluorouracil; Ganciclovir; Genetic Engineering; Genetic Th | 2016 |
Dihydropyrimidine Dehydrogenase Is a Prognostic Marker for Mesenchymal Stem Cell-Mediated Cytosine Deaminase Gene and 5-Fluorocytosine Prodrug Therapy for the Treatment of Recurrent Gliomas.
Topics: Animals; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cytosine Deaminase; Dihydrouracil Dehy | 2016 |
"Tag Team" Glioblastoma Therapy: Results From a Phase 1 Trial of Toca 511 and 5-Fluorocytosine for Recurrent High-Grade Glioma.
Topics: Brain Neoplasms; Flucytosine; Glioblastoma; Glioma; Humans | 2016 |
Antitumor efficiency of the cytosine deaminase/5-fluorocytosine suicide gene therapy system on malignant gliomas: an in vivo study.
Topics: Animals; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cytosine Deaminase; DNA Primers; Es | 2009 |
Pharmacokinetics and the bystander effect in CD::UPRT/5-FC bi-gene therapy of glioma.
Topics: Animals; Antimetabolites; Cell Line; Cytosine Deaminase; Flucytosine; Genetic Therapy; Glioma; Human | 2009 |
Human neural stem cells transduced with IFN-beta and cytosine deaminase genes intensify bystander effect in experimental glioma.
Topics: Animals; Bystander Effect; Cell Line, Tumor; Cytosine Deaminase; Disease Models, Animal; Female; Flu | 2010 |
Comparative analysis of enzyme and pathway engineering strategies for 5FC-mediated suicide gene therapy applications.
Topics: Animals; Artificial Gene Fusion; Cell Line, Tumor; Cytosine Deaminase; Disease Models, Animal; Flucy | 2011 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
The antitumor effect of mesenchymal stem cells transduced with a lentiviral vector expressing cytosine deaminase in a rat glioma model.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Genetic Ther | 2012 |
Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Coculture Techniques; Cytosine Deaminase; | 2012 |
Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy.
Topics: Animals; Brain Neoplasms; Cells, Cultured; Cytosine Deaminase; Escherichia coli; Flucytosine; Fluoro | 2003 |
Effects of CD/5-FC suicide gene therapy system on human malignant glioma cells in vitro.
Topics: Cell Death; Cell Division; Culture Media; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic The | 2003 |
Apoptosis induction with 5-fluorocytosine/cytosine deaminase gene therapy for human malignant glioma cells mediated by adenovirus.
Topics: Adenoviridae; Antimetabolites; Apoptosis; Caspase 3; Caspase 9; Caspase Inhibitors; Caspases; Cytoch | 2004 |
Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Ganciclovir; Genes, Transgeni | 2005 |
Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.
Topics: Adenoviridae; Adenovirus E1A Proteins; Base Sequence; Blotting, Western; Cell Line, Tumor; Chromatog | 2005 |
[Effects of CD/5-FC suicide gene therapy system on human malignant glioma cells in vitro].
Topics: Brain Neoplasms; Cytosine Deaminase; Flucytosine; Fluorouracil; Gene Transfer Techniques; Genetic Th | 2004 |
Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma.
Topics: Animals; Antimetabolites; Brain Neoplasms; Cell Line, Tumor; Flucytosine; Genes, Transgenic, Suicide | 2005 |
Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Disease Models, Animal; DNA, Viral; Encep | 2006 |
Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma.
Topics: Adenoviridae; Animals; Antimetabolites; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy | 2007 |
Human neural stem cells target and deliver therapeutic gene to experimental leptomeningeal medulloblastoma.
Topics: Animals; Antimetabolites; Bystander Effect; Cell Line; Cell Line, Tumor; Cell Movement; Cisterna Mag | 2007 |
Cryptococcal meningitis in patients with glioma: a report of two cases.
Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alk | 2008 |
[Antineoplastic effect of 5-fluorocytosine and cytosine deaminase on brain tumor (author's transl)].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cytosine; Cytosine Deaminase; Drug Therapy, Combina | 1982 |
Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine.
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Cytosine Deaminase; Drug Resistance, Neop | 1997 |
5-Fluorocytosine-mediated apoptosis and DNA damage in glioma cells engineered to express cytosine deaminase and their enhancement with interferon.
Topics: 3T3 Cells; Animals; Apoptosis; Cytosine Deaminase; DNA; DNA Damage; Drug Synergism; Flucytosine; Gli | 1998 |
[Experimental treatment of brain tumor cells using CD suicide gene].
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Cytosine Deaminase; Escherichia coli; Flu | 1996 |
In vivo and in vitro glioma cell killing induced by an adenovirus expressing both cytosine deaminase and thymidine kinase and its association with interferon-alpha.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Brain; Brain Neoplasms; Cell Survival; Cyto | 1999 |
In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Brain; Brain Neoplasms; Cytosine Deaminase; | 2000 |
Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy.
Topics: Animals; Antifungal Agents; Brain Neoplasms; Cytosine Deaminase; Flucytosine; Genetic Therapy; Gliom | 2000 |
Combined antitumor effects of an adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma.
Topics: Adenoviridae; Animals; Antimetabolites; Antiviral Agents; Artificial Gene Fusion; Brain Neoplasms; C | 2000 |
Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model.
Topics: Animals; Antiviral Agents; Cytosine Deaminase; Escherichia coli; Female; Flucytosine; Ganciclovir; G | 2002 |
Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules.
Topics: Animals; Brain Neoplasms; Capsules; Cytosine; Cytosine Deaminase; Drug Evaluation, Preclinical; Drug | 1985 |